Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024923015693 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849336028860514304 |
|---|---|
| author | Lisa Daniel-Fischer Marlies Antlanger Daniel Cejka Kathrin Eller Philipp Gauckler Balazs Odler Michael Rudnicki Marcus D. Säemann Alice Schmidt Gere Sunder-Plassmann Martin Wiesholzer Martin Windpessl Emanuel Zitt Franz Koenig Larry A. Greenbaum Andreas Kronbichler Christoph Aufricht |
| author_facet | Lisa Daniel-Fischer Marlies Antlanger Daniel Cejka Kathrin Eller Philipp Gauckler Balazs Odler Michael Rudnicki Marcus D. Säemann Alice Schmidt Gere Sunder-Plassmann Martin Wiesholzer Martin Windpessl Emanuel Zitt Franz Koenig Larry A. Greenbaum Andreas Kronbichler Christoph Aufricht |
| author_sort | Lisa Daniel-Fischer |
| collection | DOAJ |
| format | Article |
| id | doaj-art-08e32e17c7e94d2199f321fbf167c3cd |
| institution | Kabale University |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-08e32e17c7e94d2199f321fbf167c3cd2025-08-20T03:45:06ZengElsevierKidney International Reports2468-02492024-02-019247848110.1016/j.ekir.2023.10.027Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial DesignLisa Daniel-Fischer0Marlies Antlanger1Daniel Cejka2Kathrin Eller3Philipp Gauckler4Balazs Odler5Michael Rudnicki6Marcus D. Säemann7Alice Schmidt8Gere Sunder-Plassmann9Martin Wiesholzer10Martin Windpessl11Emanuel Zitt12Franz Koenig13Larry A. Greenbaum14Andreas Kronbichler15Christoph Aufricht16Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine 2, Faculty of Medicine, Kepler University Hospital, Johannes Kepler University, Linz, AustriaDepartment of Internal Medicine 3 - Kidney and High-Pressure Diseases, Transplantation Medicine, Rheumatology, Ordensklinikum Linz-Elisabethinen, Linz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria6th Medical Department with Nephrology and Dialysis, Clinic Ottakring Vienna, Vienna, Austria; Medical Faculty, Sigmund-Freud University, Vienna, AustriaDepartment of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, AustriaDepartment of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, AustriaClinical Department for Internal Medicine, University Hospital St Poelten, Karl Landsteiner University of Health Sciences, St Poelten, AustriaDepartment of Internal Medicine IV, Section of Nephrology, Clinic Wels-Grieskirchen, Wels, Austria; Medical Faculty, Johannes Kepler University Linz, Linz, AustriaDepartment of Internal Medicine III (Nephrology, Dialysis and Hypertension), Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, AustriaCenter for Medical Data Science, Medical University of Vienna, Vienna, AustriaDivision of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USADepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, AustriaDivision of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria; Correspondence: Christoph Aufricht, Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.http://www.sciencedirect.com/science/article/pii/S2468024923015693clopidogreldrug repurposingFSGSproteinuria |
| spellingShingle | Lisa Daniel-Fischer Marlies Antlanger Daniel Cejka Kathrin Eller Philipp Gauckler Balazs Odler Michael Rudnicki Marcus D. Säemann Alice Schmidt Gere Sunder-Plassmann Martin Wiesholzer Martin Windpessl Emanuel Zitt Franz Koenig Larry A. Greenbaum Andreas Kronbichler Christoph Aufricht Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design Kidney International Reports clopidogrel drug repurposing FSGS proteinuria |
| title | Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design |
| title_full | Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design |
| title_fullStr | Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design |
| title_full_unstemmed | Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design |
| title_short | Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design |
| title_sort | clopidogrel for proteinuria reduction in focal segmental glomerulosclerosis phase 2 trial design |
| topic | clopidogrel drug repurposing FSGS proteinuria |
| url | http://www.sciencedirect.com/science/article/pii/S2468024923015693 |
| work_keys_str_mv | AT lisadanielfischer clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT marliesantlanger clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT danielcejka clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT kathrineller clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT philippgauckler clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT balazsodler clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT michaelrudnicki clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT marcusdsaemann clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT aliceschmidt clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT geresunderplassmann clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT martinwiesholzer clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT martinwindpessl clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT emanuelzitt clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT franzkoenig clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT larryagreenbaum clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT andreaskronbichler clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign AT christophaufricht clopidogrelforproteinuriareductioninfocalsegmentalglomerulosclerosisphase2trialdesign |